Vascular Cytochrome P450 Enzymes: Physiology and Pathophysiology

Trends in Cardiovascular Medicine

Volumn 18, Issue 1, 2008, Pages 20-25

  Fleming, Ingrid ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID;

ANGIOGENESIS; BLOOD VESSEL TONE; ENZYME REGULATION; GENETIC POLYMORPHISM; INFLAMMATION; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VASODILATATION;

ANIMALS; ARACHIDONIC ACID; CYTOCHROME P-450 ENZYME SYSTEM; EPOXIDE HYDROLASES; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; INFLAMMATION; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR DISEASES; VASODILATION;

EID: 38149070234     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2007.11.002     Document Type: Review

References (57)

1. Ai D., Fu Y., Guo D., et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 104 (2007) 9018-9023
2. Bellien J., Iacob M., Gutierrez L., et al. Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation. Hypertension 48 (2006) 1088-1094
3. Bellien J., Joannides R., Iacob M., et al. Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol 290 (2006) H1347-H1352
4. Bergheim I., Wolfgarten E., Bollschweiler E., et al. Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma. World J Gastroenterol 13 (2007) 997-1002
5. Busse R., Edwards G., Feletou M., et al. EDHF: bringing the concepts together. Trends Pharmacol Sci 23 (2002) 374-380
6. Chehal M.K., and Granville D.J. Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction. Can J Physiol Pharmacol 84 (2006) 15-20
7. Davis B.B., Thompson D.A., Howard L.L., et al. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A 99 (2002) 2222-2227
8. Dreisbach A.W., Japa S., Sigel S., et al. The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens 18 (2005) 1276-1281
9. Fang X., Hu S., Watanabe T., et al. Activation of peroxisome proliferator-activated receptor a by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 314 (2005) 260-270
10. Fichtlscherer S., Dimmeler S., Breuer S., et al. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 109 (2004) 178-183
11. Firth A.L., Remillard C.V., and Yuan J.X.J. TRP channels in hypertension. Biochim Biophys Acta (BBA)-Molecular Basis of Disease 1772 (2007) 895-906
12. Fischer D., Landmesser U., Spiekermann S., et al. Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail 9 (2007) 770-775
13. Fisslthaler B., Popp R., Kiss L., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401 (1999) 493-497
14. Fleming I. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Trends Cardiovasc Med 10 (2000) 166-170
15. Fleming I., Michaelis U.R., Bredenkötter D., et al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88 (2001) 44-51
16. Fleming I., Rueben A., Popp R., et al. Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol (2007) (in press)
17. Fornage M., Boerwinkle E., Doris P.A., et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109 (2004) 335-339
18. Fornage M., Lee C.R., Doris P.A., et al. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 14 (2005) 2829-2837
19. Hillig T., Krustrup P., Fleming I., et al. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol (Lond) 546 (2003) 307-314
20. Hutchens M.P., Nakano T., Dunlap J., et al. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation (2007) (in press)
21. Imig J.D. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289 (2005) F496-F503
22. Jacobs E.R., and Zeldin D.C. The lung HETEs (and EETs) up. Am J Physiol Heart Circ Physiol 280 (2001) H1-H10
23. Jiang J.G., Chen C.L., Card J.W., et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65 (2005) 4707-4715
24. Jiang J.G., Ning Y.G., Chen C., et al. Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Res 67 (2007) 6665-6674
25. King L.M., Gainer J.V., David G.L., et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenomics 15 (2005) 7-13
26. Koerner I.P., Jacks R., DeBarber A.E., et al. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J Neurosci 27 (2007) 4642-4649
27. Larsen B.T., Campbell W.B., and Gutterman D.D. Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol Sci 28 (2007) 32-38
28. Lee C.R., North K.E., Bray M.S., et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15 (2006) 1640-1649
29. Lee C.R., North K.E., Bray M.S., et al. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenomics 17 (2007) 349-358
30. Liu P.Y., Li Y.H., Chao T.H., et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 195 (2007) 199-206
31. Maresh J.G., Xu H., Jiang N., et al. Tobacco smoke dysregulates endothelial vasoregulatory transcripts in vivo. Physiol Genomics 21 (2005) 308-313
32. Medhora M., Daniels J., Mundey K., et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 284 (2003) H215-H224
33. Michaelis U.R., and Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther 111 (2006) 584-595
34. Michaelis U.R., Fisslthaler B., Barbosa-Sicard E., et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 118 (2005) 5489-5498
35. Moghaddam M.F., Grant D.F., Cheek J.M., et al. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med 3 (1997) 562-566
36. Munzenmaier D.H., and Harder D.R. Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol 278 (2000) H1163-H1167
37. Ohtoshi K., Kaneto H., Node K., et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem Biophys Res Commun 331 (2005) 347-350
38. Pang S.T., Dillner K., Wu X., et al. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology 143 (2002) 4897-4906
39. Passauer J., Büssemaker E., Lassig G., et al. Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the CYP 2C9 inhibitor sulfaphenazole. Clin Sci (Lond) 105 (2003) 513-518
40. Passauer J., Pistrosch F., Lässig G., et al. Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9. Kidney Int 67 (2005) 1907-1912
41. Pinot F., Grant D.F., Spearow J.L., et al. Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice. Biochem Pharmacol 50 (1995) 501-508
42. Pokreisz P., Fleming I., Kiss L., et al. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 47 (2006) 762-770
43. Przybyla-Zawislak B.D., Srivastava P.K., Vazquez-Matias J., et al. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 64 (2003) 482-490
44. Sandberg M., Hassett C., Adman E.T., et al. Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J Biol Chem 275 (2000) 28873-28881
45. Sato K., Emi M., Ezura Y., et al. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet 49 (2004) 29-34
46. Schmelzer K.R., Kubala L., Newman J.W., et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 102 (2005) 9772-9777
47. Smith K.R., Pinkerton K.E., Watanabe T., et al. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A 102 (2005) 2186-2191
48. Spector A.A., and Norris A.W. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292 (2007) C996-C1012
49. Spiecker M., and Liao J. Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease. Trends Cardiovasc Med 16 (2006) 204-208
50. Spiecker M., Darius H., Hankeln T., et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110 (2004) 2132-2136
51. Wang Y., Wei X., Xiao X., et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 314 (2005) 522-532
52. Watanabe H., Vriens J., Prenen J., et al. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424 (2003) 434-438
53. Wei Q., Doris P.A., Pollizotto M.V., et al. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 190 (2007) 26-34
54. Weissmann N., Dietrich A., Fuchs B., et al. Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U S A 103 (2006) 19093-19098
55. Yu Z., Xu F., Huse L.M., et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87 (2000) 992-998
56. Yu B.N., Luo C.H., Wang D., et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 348 (2004) 57-61
57. Zheng J., Plopper C.G., Lakritz J., et al. Leukotoxin-diol. A putative toxic mediator involved in acute respiratory distress syndrome. Am J Respir Cell Mol Biol 25 (2001) 434-438